bluebird bio Inc  

(Public, NASDAQ:BLUE)   Watch this stock  
Find more results for BLUE
+0.50 (0.38%)
After Hours: 130.70 -0.11 (-0.08%)
Sep 20, 7:16PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 127.90 - 133.00
52 week 37.05 - 136.85
Open 130.30
Vol / Avg. 0.00/888,054.00
Mkt cap 5.96B
P/E     -
Div/yield     -
EPS -7.36
Shares 45.59M
Beta 2.03
Inst. own 110%
Oct 31, 2017
Q3 2017 bluebird bio Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 28, 2017
bluebird bio Inc at Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology - 9:30AM EDT - Add to calendar
Sep 13, 2017
bluebird bio Inc at Morgan Stanley Healthcare Conference - Webcast
Sep 7, 2017
bluebird bio Inc at Wells Fargo Healthcare Conference
Aug 15, 2017
bluebird bio Inc at Wedbush PacGrow Healthcare Conference - Webcast
Aug 2, 2017
Q2 2017 bluebird bio Inc Earnings Release
Aug 1, 2017
bluebird bio Inc at Wells Fargo Boston Biotech Corporate Access Day
Jun 23, 2017
bluebird bio Inc EHA Data Review Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -424.13% -4281.19%
Operating margin -405.73% -4351.42%
EBITD margin - -4193.83%
Return on average assets -22.48% -24.85%
Return on average equity -28.22% -30.64%
Employees 378 -
CDP Score - -


60 Binney St
CAMBRIDGE, MA 02142-1512
United States - Map
+1-339-4999300 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Officers and directors

Daniel S. Lynch Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Nick Leschly President, Chief Executive Officer, Director
Age: 44
Bio & Compensation  - Reuters
Jeffrey T. Walsh Chief Financial and Strategy Officer and Principal Financial Officer, Principal Accounting Officer
Age: 51
Bio & Compensation  - Reuters
Susanna Gatti High Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
Philip D. Gregory Ph.D. Chief Scientific Officer
Age: 46
Bio & Compensation  - Reuters
David M. Davidson M.D. Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Jason F. Cole Esq. Chief Legal Officer, Secretary
Age: 44
Bio & Compensation  - Reuters
John O. Agwunobi M.D. Director
Age: 52
Bio & Compensation  - Reuters
Douglas A. Melton Director
Bio & Compensation  - Reuters
Wendy L. Dixon Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters